Credit Suisse’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-164,035
| Closed | -$673K | – | 4595 |
|
|
2022
Q1 | $673K | Buy |
164,035
+8,564
| +6% | +$31.1K | ﹤0.01% | 2804 |
|
|
2021
Q4 | $556K | Sell |
155,471
-7,906
| -5% | -$27.6K | ﹤0.01% | 3741 |
|
|
2021
Q3 | $595K | Buy |
163,377
+7,120
| +5% | +$28.8K | ﹤0.01% | 3702 |
|
|
2021
Q2 | $682K | Buy |
156,257
+23,510
| +18% | +$95.8K | ﹤0.01% | 3645 |
|
|
2021
Q1 | $546K | Sell |
132,747
-53,505
| -29% | -$232K | ﹤0.01% | 3708 |
|
|
2020
Q4 | $743K | Buy |
186,252
+49,732
| +36% | +$161K | ﹤0.01% | 3561 |
|
|
2020
Q3 | $368K | Buy |
136,520
+15,995
| +13% | +$44.3K | ﹤0.01% | 3540 |
|
|
2020
Q2 | $331K | Buy |
120,525
+39,101
| +48% | +$109K | ﹤0.01% | 3533 |
|
|
2020
Q1 | $193K | Sell |
81,424
-40,778
| -33% | -$139K | ﹤0.01% | 3660 |
|
|
2019
Q4 | $574K | Buy |
122,202
+36,561
| +43% | +$150K | ﹤0.01% | 3481 |
|
|
2019
Q3 | $286K | Sell |
85,641
-17,457
| -17% | -$57.5K | ﹤0.01% | 3723 |
|
|
2019
Q2 | $340K | Buy |
103,098
+22,378
| +28% | +$64.7K | ﹤0.01% | 3620 |
|
|
2019
Q1 | $246K | Buy |
80,720
+6,684
| +9% | +$21.7K | ﹤0.01% | 3695 |
|
|
2018
Q4 | $201K | Buy |
+74,036
| New | +$244K | ﹤0.01% | 3669 |
|
|
2018
Q3 | – | Sell |
-37,436
| Closed | -$96K | – | 4069 |
|
|
2018
Q2 | $96K | Sell |
37,436
-12,981
| -26% | -$32.3K | ﹤0.01% | 3841 |
|
|
2018
Q1 | $111K | Buy |
50,417
+8,984
| +22% | +$20.2K | ﹤0.01% | 3789 |
|
|
2017
Q4 | $82K | Sell |
41,433
-52,608
| -56% | -$114K | ﹤0.01% | 3863 |
|
|
2017
Q3 | $305K | Buy |
94,041
+63,597
| +209% | +$196K | ﹤0.01% | 3736 |
|
|
2017
Q2 | $99K | Sell |
30,444
-21,088
| -41% | -$59.8K | ﹤0.01% | 3721 |
|
|
2017
Q1 | $146K | Buy |
+51,532
| New | +$124K | ﹤0.01% | 3660 |
|
|
2016
Q3 | – | Sell |
-537,318
| Closed | -$565K | – | 4317 |
|
|
2016
Q2 | $565K | Buy |
537,318
+515,478
| +2,360% | +$498K | ﹤0.01% | 3344 |
|
|
2016
Q1 | $19K | Sell |
21,840
-12,105
| -36% | -$11.7K | ﹤0.01% | 3927 |
|
|
2015
Q4 | $41K | Sell |
33,945
-59,770
| -64% | -$83.2K | ﹤0.01% | 4145 |
|
|
2015
Q3 | $159K | Sell |
93,715
-59,189
| -39% | -$116K | ﹤0.01% | 4004 |
|
|
2015
Q2 | $318K | Buy |
152,904
+107,492
| +237% | +$261K | ﹤0.01% | 3992 |
|
|
2015
Q1 | $122K | Sell |
45,412
-48,797
| -52% | -$124K | ﹤0.01% | 4193 |
|
|
2014
Q4 | $242K | Buy |
94,209
+40,788
| +76% | +$91.6K | ﹤0.01% | 4187 |
|
|
2014
Q3 | $98K | Sell |
53,421
-170,188
| -76% | -$371K | ﹤0.01% | 4299 |
|
|
2014
Q2 | $599K | Buy |
223,609
+44,970
| +25% | +$135K | ﹤0.01% | 3697 |
|
|
2014
Q1 | $625K | Buy |
178,639
+43,873
| +33% | +$195K | ﹤0.01% | 3540 |
|
|
2013
Q4 | $603K | Buy |
134,766
+6,271
| +5% | +$25.6K | ﹤0.01% | 3651 |
|
|
2013
Q3 | $522K | Buy |
128,495
+99,107
| +337% | +$433K | ﹤0.01% | 3471 |
|
|
2013
Q2 | $122K | Buy |
+29,388
| New | +$114K | ﹤0.01% | 3980 |
|
Other funds holding ATRS
Credit Suisse's ATRS Position: Q2 2022 in Review
Credit Suisse sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 164,035 shares — an estimated $673K sold.
Credit Suisse first reported a position in ATRS in Q2 2013 and held it in 33 quarters. The position peaked at $743K in Q4 2020. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Credit Suisse reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Credit Suisse sold 164,035 Antares Pharma, Inc. shares in Q2 2022, an estimated $673K.
- Credit Suisse first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 33 quarters.
- Credit Suisse's Antares Pharma, Inc. position peaked at $743K in Q4 2020.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Credit Suisse's 13F filing for Q2 2022, filed 12 Aug 2022.